This clinical trial is focused on studying a condition called Pulmonary Arterial Hypertension (PAH). PAH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The study will use a treatment called sotatercept, which is also known by its code name MK-7962. Sotatercept is a solution for injection and is being tested to see how it behaves in the body and how safe it is for people with PAH.

The purpose of the study is to understand how sotatercept is absorbed and processed in the body when given in different ways based on a person’s weight. Participants will receive sotatercept through a subcutaneous injection, which means it is injected under the skin. The study will last for 24 weeks, during which participants will receive multiple doses of the medication. Researchers will monitor the levels of sotatercept in the blood and check for any side effects or adverse events that may occur during the treatment period.

By participating in this study, researchers aim to gather important information about the safety and effectiveness of sotatercept for treating PAH. This information could help improve treatment options for people living with this condition. The study will not only look at how the drug is processed in the body but also ensure that it is safe and well-tolerated by participants over the course of the treatment.